(year mean/median +SD or range) / Definition of ovarian dysfunction / Type of hormonal treatment
(GnRHa, OCP), dosing, timing / Study size / Study population / Study (Author, year, location)
control / study / control / study / N control / N study
B,B,B / 2.0y
(1-2.5) / 2.3y
(1.8-2.5) / MVPP / 25.9 (mean) / 28.5 (mean) / Amenorrhea
Ovulation (P2)
Pregnancy / Buserelin 200ugm x3/day intranasaly / 10 / 8 / Hodgkin's disease / Waxman 1987;USA
B,B,B / 5.9y / 2.4y / ABVD, MOPP/ABVD / 30.2 (mean) / 26.7 (mean) / Cyclic ovarian function (=menstruation)
AMH
Inhibin
FSH
Follicles on TVS
Pregnancy / D-TRP-GnRH, Decapeptyl, Triptorelin 3.75mg IM q4w or depot 11.25mg q3mo / 15 / 14 / Hodgkin's disease / Giuseppe; 2007;Italy
B,B,B / 18-30
months / 18-30
months / Adjuvant chemotherapy for breast cancer (not specified) / 34 (median)
Range 21-43 / 34 (median)
Range 21-43 / Amenorrhea
AMH
Inhibin
FSH
Pregnancy / D-TRP-GnRH,Decapeptyl, Triptorelin 3.75mg IM / 26 / 23 / Breast Cancer / Ismail-Kahn
2008
A,A,B / 8 months / 8 months / FAC / 29.2+2.93 / 30+3.51 / Cyclic ovarian function (=menstruation)
Amenorrhea
AMH
Inhibin
FSH
LH
Pregnancy / Goserelin, 3.6mg SC14 / 39 / 39 / Breast Cancer / Badawy 2009; Egypt
A,A,B / 36 months / 36 months / CMF / 46 (median)
Range 36-55 / 45 (median)
Range 29-54 / Cyclic ovarian function (=menstruation)
Amenorrhea / Goserelin 3.6mg q28d / 63 / 63 / Breast Cancer / Sverrisdottir 2009
Sweden
a The first letter is a grade for allocation generation, and the second letter is a grade for allocation concealment; both are graded as A for adequate and B for unclear or unknown methods.
The thirdletter denotes blinding: DB, double-blind; OL, open-label, OA, outcome assessor.